MDxHealth Receives Nasdaq Warning Letter
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: NASDAQ.COM
- Nasdaq Warning: MDxHealth received a notification from the Nasdaq Listing Qualifications Department on June 30, 2026, for failing to maintain a minimum bid price of $1.00 per share, violating Nasdaq Listing Rule 5550 (a)(2), which could negatively impact the company's market image and investor confidence.
- Compliance Deadline: The company has been granted 180 days until December 28, 2026, to regain compliance, requiring its ordinary shares to close at a minimum of $1.00 for 10 consecutive trading days, which is crucial for its financial health.
- Stock Performance: MDxHealth closed at $0.48 on Thursday, down 6.02%, and further dropped 5.65% to $0.45 in after-hours trading, indicating increasing market concerns regarding its ability to comply in the future.
- Potential Consequences: Failure to regain compliance by the deadline may lead to delisting, although the company could be eligible for additional time, which would significantly affect its financing capabilities and market position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDXH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDXH
Wall Street analysts forecast MDXH stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.483
Low
7.00
Averages
7.67
High
9.00
Current: 0.483
Low
7.00
Averages
7.67
High
9.00
About MDXH
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MDxHealth Receives Nasdaq Warning Letter
- Nasdaq Warning: MDxHealth received a notification from the Nasdaq Listing Qualifications Department on June 30, 2026, for failing to maintain a minimum bid price of $1.00 per share, violating Nasdaq Listing Rule 5550 (a)(2), which could negatively impact the company's market image and investor confidence.
- Compliance Deadline: The company has been granted 180 days until December 28, 2026, to regain compliance, requiring its ordinary shares to close at a minimum of $1.00 for 10 consecutive trading days, which is crucial for its financial health.
- Stock Performance: MDxHealth closed at $0.48 on Thursday, down 6.02%, and further dropped 5.65% to $0.45 in after-hours trading, indicating increasing market concerns regarding its ability to comply in the future.
- Potential Consequences: Failure to regain compliance by the deadline may lead to delisting, although the company could be eligible for additional time, which would significantly affect its financing capabilities and market position.
See More
Mdxhealth SA Receives Nasdaq Compliance Notice
- Compliance Notice: Mdxhealth SA received a Nasdaq notice for non-compliance due to its shares failing to maintain a minimum bid price of $1 for 30 consecutive days, although this notice does not currently affect its listing status.
- Compliance Deadline: The company has 180 days, until December 28, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days, which is critical for its continued listing.
- Potential Consequences: If compliance is not regained, the company may receive additional time or face delisting, which could negatively impact its market reputation and ability to raise capital.
- Response Measures: Mdxhealth SA stated it will monitor its share price and may consider options such as a reverse stock split to regain compliance if necessary, demonstrating its commitment to maintaining its listing status.
See More
MDxHealth SA Q1 Earnings Report Analysis
- Disappointing Earnings: MDxHealth SA reported a Q1 GAAP EPS of -$0.17, missing expectations by $0.02, indicating ongoing pressure on profitability that may affect investor confidence.
- Lackluster Revenue Growth: Revenue increased by 12.7% year-over-year to $27.38M, yet fell short of expectations by $3.42M, reflecting unmet market demand that could pose challenges for future performance.
- Declining Gross Margin: Gross margins decreased from 63.8% last year to 60.7%, a drop of 3.1 percentage points primarily due to changes in test mix, indicating pressure on cost control that may impact overall profitability.
- Rising Operating Expenses: Operating expenses rose by 19% to $23.9M year-over-year, driven mainly by increased headcount and other costs related to the ExoDx acquisition, highlighting the financial burden faced during the company's expansion efforts.
See More
MDxHealth SA Reports Q4 Earnings Miss
- Earnings Report Disappointment: MDxHealth SA's Q4 GAAP EPS of -$0.17 missed expectations by $0.04, indicating challenges in profitability that could undermine investor confidence moving forward.
- Lackluster Revenue Growth: The company reported Q4 revenue of $29.5 million, a 19.4% year-over-year increase, yet it fell short of expectations by $1.33 million, reflecting intensified market competition and potential shortcomings in sales strategies.
- Future Sales Outlook: MDxHealth anticipates FY25 net sales of up to $109 million, suggesting growth potential; however, confidence in achieving this target may be dampened by the current underperformance.
- Quant Rating Analysis: Seeking Alpha's Quant Rating on MDxHealth indicates a cautious market sentiment regarding its future performance, which may lead to diminished investor interest in the stock in the short term.
See More
Mdxhealth to Present 2025 Financial Results and Corporate Update
- Earnings Release Schedule: Mdxhealth will release its financial results for Q4 and the full year ended December 31, 2025, after market close on February 26, 2026, indicating the company's ongoing development in the precision diagnostics sector.
- Conference Call Details: The company will host a conference call on February 26, 2026, at 4:30 PM ET, featuring a live Q&A session aimed at enhancing investor engagement and transparency.
- Webcast Information: The webcast will be accessible 15 minutes prior to the call, with a replay available post-event on the company’s website, ensuring that investors who cannot attend live can still access critical information.
- Company Background: Mdxhealth is a leading precision diagnostics firm focused on providing actionable molecular information to personalize patient diagnosis and treatment, primarily targeting urologic cancers and related diseases, showcasing its expertise and technological advantages in the healthcare field.
See More
MDxHealth Reports $109M Revenue for 2025, Projects 26%-28% Growth for 2026
- Significant Revenue Growth: MDxHealth expects fourth-quarter 2025 revenue of approximately $30.5 million, a 23% increase from $24.7 million in Q4 2024, indicating continued double-digit growth across its precision diagnostics portfolio.
- Full-Year Performance Boost: Projected full-year revenue for 2025 is $109 million, up 21% from $90 million in 2024, reflecting strong market performance and increased customer demand.
- Successful Product Transition: In 2025, the company sold 71,920 liquid-based units, a 57% increase, while tissue-based units totaled 49,180, up 18%, demonstrating the successful integration of the Exosome Diagnostics business.
- Optimistic Future Outlook: MDxHealth issued 2026 revenue guidance of $137 million to $140 million, representing expected growth of 26% to 28%, while aiming for a 10% adjusted EBITDA margin run rate by the end of 2026, showcasing confidence in sustained growth.
See More
MDxHealth Receives Nasdaq Warning Letter
- Nasdaq Warning: MDxHealth received a notification from the Nasdaq Listing Qualifications Department on June 30, 2026, for failing to maintain a minimum bid price of $1.00 per share, violating Nasdaq Listing Rule 5550 (a)(2), which could negatively impact the company's market image and investor confidence.
- Compliance Deadline: The company has been granted 180 days until December 28, 2026, to regain compliance, requiring its ordinary shares to close at a minimum of $1.00 for 10 consecutive trading days, which is crucial for its financial health.
- Stock Performance: MDxHealth closed at $0.48 on Thursday, down 6.02%, and further dropped 5.65% to $0.45 in after-hours trading, indicating increasing market concerns regarding its ability to comply in the future.
- Potential Consequences: Failure to regain compliance by the deadline may lead to delisting, although the company could be eligible for additional time, which would significantly affect its financing capabilities and market position.
See More
Mdxhealth SA Receives Nasdaq Compliance Notice
- Compliance Notice: Mdxhealth SA received a Nasdaq notice for non-compliance due to its shares failing to maintain a minimum bid price of $1 for 30 consecutive days, although this notice does not currently affect its listing status.
- Compliance Deadline: The company has 180 days, until December 28, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days, which is critical for its continued listing.
- Potential Consequences: If compliance is not regained, the company may receive additional time or face delisting, which could negatively impact its market reputation and ability to raise capital.
- Response Measures: Mdxhealth SA stated it will monitor its share price and may consider options such as a reverse stock split to regain compliance if necessary, demonstrating its commitment to maintaining its listing status.
See More
MDxHealth SA Q1 Earnings Report Analysis
- Disappointing Earnings: MDxHealth SA reported a Q1 GAAP EPS of -$0.17, missing expectations by $0.02, indicating ongoing pressure on profitability that may affect investor confidence.
- Lackluster Revenue Growth: Revenue increased by 12.7% year-over-year to $27.38M, yet fell short of expectations by $3.42M, reflecting unmet market demand that could pose challenges for future performance.
- Declining Gross Margin: Gross margins decreased from 63.8% last year to 60.7%, a drop of 3.1 percentage points primarily due to changes in test mix, indicating pressure on cost control that may impact overall profitability.
- Rising Operating Expenses: Operating expenses rose by 19% to $23.9M year-over-year, driven mainly by increased headcount and other costs related to the ExoDx acquisition, highlighting the financial burden faced during the company's expansion efforts.
See More
MDxHealth SA Reports Q4 Earnings Miss
- Earnings Report Disappointment: MDxHealth SA's Q4 GAAP EPS of -$0.17 missed expectations by $0.04, indicating challenges in profitability that could undermine investor confidence moving forward.
- Lackluster Revenue Growth: The company reported Q4 revenue of $29.5 million, a 19.4% year-over-year increase, yet it fell short of expectations by $1.33 million, reflecting intensified market competition and potential shortcomings in sales strategies.
- Future Sales Outlook: MDxHealth anticipates FY25 net sales of up to $109 million, suggesting growth potential; however, confidence in achieving this target may be dampened by the current underperformance.
- Quant Rating Analysis: Seeking Alpha's Quant Rating on MDxHealth indicates a cautious market sentiment regarding its future performance, which may lead to diminished investor interest in the stock in the short term.
See More
Mdxhealth to Present 2025 Financial Results and Corporate Update
- Earnings Release Schedule: Mdxhealth will release its financial results for Q4 and the full year ended December 31, 2025, after market close on February 26, 2026, indicating the company's ongoing development in the precision diagnostics sector.
- Conference Call Details: The company will host a conference call on February 26, 2026, at 4:30 PM ET, featuring a live Q&A session aimed at enhancing investor engagement and transparency.
- Webcast Information: The webcast will be accessible 15 minutes prior to the call, with a replay available post-event on the company’s website, ensuring that investors who cannot attend live can still access critical information.
- Company Background: Mdxhealth is a leading precision diagnostics firm focused on providing actionable molecular information to personalize patient diagnosis and treatment, primarily targeting urologic cancers and related diseases, showcasing its expertise and technological advantages in the healthcare field.
See More
MDxHealth Reports $109M Revenue for 2025, Projects 26%-28% Growth for 2026
- Significant Revenue Growth: MDxHealth expects fourth-quarter 2025 revenue of approximately $30.5 million, a 23% increase from $24.7 million in Q4 2024, indicating continued double-digit growth across its precision diagnostics portfolio.
- Full-Year Performance Boost: Projected full-year revenue for 2025 is $109 million, up 21% from $90 million in 2024, reflecting strong market performance and increased customer demand.
- Successful Product Transition: In 2025, the company sold 71,920 liquid-based units, a 57% increase, while tissue-based units totaled 49,180, up 18%, demonstrating the successful integration of the Exosome Diagnostics business.
- Optimistic Future Outlook: MDxHealth issued 2026 revenue guidance of $137 million to $140 million, representing expected growth of 26% to 28%, while aiming for a 10% adjusted EBITDA margin run rate by the end of 2026, showcasing confidence in sustained growth.
See More
